J&J agrees to pay US$2.2 billion in Risperdal settlement: report


AP

NEW YORK — Johnson & Johnson has agreed to pay as much as US$2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report.

The Wall Street Journal, which reported the settlement Thursday, said the settlement will include a US$400 million criminal fine and that the final amount will depend on how many states accept the settlement.

Johnson & Johnson and the U.S. Department of Justice both declined to comment.

The Journal said Johnson & Johnson will disclose the general terms of the settlement in the next few weeks, and that the company will still be allowed to sell its products to Medicare and other government health care programs.